"Work" and "Defense" to Seek "Win-Win"
Release time:
2020-07-15
At present, for most areas outside Hubei Province, resuming work and recovering the losses caused by the epidemic is undoubtedly the core content of the current work. In terms of the company's situation, although enterprises have resumed work one after another after the end of the Spring Festival holiday, due to the overall market has not recovered, logistics and people flow are still blocked, and the employee arrival rate and actual production level of most enterprises are far from reaching the normal level. This situation not only brings pressure to the management team of each enterprise, but also adversely affects the completion of the company's annual target.
Resuming work and production as soon as possible and reaching production standards is not only the need for the company's management and development, but also the need to stabilize the enterprise order and do a better job of epidemic prevention and control. If the work of the enterprise is stagnant for a long time, it will not only cause the paralysis of the enterprise market and the loss of profits, but also cause the staff to be distracted, and it is difficult to promote all kinds of work. This "all", of course, also includes epidemic prevention and control. Therefore, the Central Conference on Epidemic Prevention and Control proposed that the resumption of work and production is "another battlefield" to fight the battle of epidemic prevention and control ".
With the recent warming of the weather, especially the lowering of the emergency response level, it is not difficult to find the gradual "optimistic phenomenon" around us: some people who wore masks well before began to wear them, and the daily disinfection became not "daily", and the situation of gathering together has increased... In view of these phenomena, we still need to remind employees that it is not yet time to take off masks and have a good drink, epidemic prevention and control does not have a trace of fault tolerance space, can not tolerate the slightest paralysis, do a good job of daily protection, do not leave prevention and control loopholes, but also every enterprise, every employee needs to pay attention to the problem,.
Only when the alarm bell rings can we always catch it. Therefore, managers at all levels should properly handle the relationship between the prevention and control of the epidemic and the resumption of work and production, grasp the prevention and control of the epidemic while resuming work and production, and resume production as soon as possible under the condition of grasping the prevention and control of the epidemic. Only by attaching equal importance to both "work" and "prevention" can we achieve a win-win situation in production and operation and epidemic prevention and control in this special period and win this special battle. (one word)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page